Drugs / RTXM83
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02268045 | May 2013 → May 2016 | diffuse large B-cell lymphoma | mAbxience Research S.L. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RTXM83 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02268045 ↗ |